Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Denali Therapeutics (DNLI) Leases (2019 - 2026)

Denali Therapeutics has reported Leases over the past 7 years, most recently at $48.5 million for Q4 2025.

  • Quarterly Leases rose 2.1% to $48.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.5 million through Dec 2025, up 2.1% year-over-year, with the annual reading at $48.5 million for FY2025, 2.1% up from the prior year.
  • Leases was $48.5 million for Q4 2025 at Denali Therapeutics, up from $20.0 million in the prior quarter.
  • Over five years, Leases peaked at $48.5 million in Q4 2025 and troughed at $20.0 million in Q3 2025.
  • The 5-year median for Leases is $30.0 million (2022), against an average of $30.7 million.
  • The largest YoY upside for Leases was 93.21% in 2025 against a maximum downside of 15.52% in 2025.
  • A 5-year view of Leases shows it stood at $30.7 million in 2021, then dropped by 1.0% to $30.4 million in 2022, then fell by 14.42% to $26.0 million in 2023, then soared by 82.48% to $47.5 million in 2024, then rose by 2.1% to $48.5 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Leases are $48.5 million (Q4 2025), $20.0 million (Q3 2025), and $47.4 million (Q2 2025).